"JNJ's prostate cancer drug test was halted early because the results were clear: "An independent data monitoring panel stopped the study early based on findings which showed that the Zytiga therapy significantly delayed the growth of prostate cancer and helped patients live longer compared to placebo."
When will be a possibly potential halt for imuc clinical trial?
If the P2 data mirror the P1, with over 100 patients enrolled, the difference in OS and PFS should be significant by the time of 50% deaths in the control group. If this turns out to be the case, the trial will almost certainly be halted early and control patients will be allowed to cross over. I would expect an announcement to this effect in Q4/12 or Q1/13. And there will be no additional trial required prior to approval--this is the pivotal trial.